Perifosine (KRX-0401)

Catalog No.S1037 Synonyms: NSC639966

Perifosine (KRX-0401) Chemical Structure

Molecular Weight(MW): 461.66

Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 49 Publications

16 Customer Reviews

  • Tumor growth of 827 GSC-derived xenografts treated with an AKT inhibitor perifosine (30 mg/kg body weight). Twenty-three days after tumor implantation in mice, perifosine was administered by intraperitoneal injection (daily for 5 days). Error bars represent SD. Five mice per group, *p < 0.01.

    Cancer Cell 2013 23, 839-52. Perifosine (KRX-0401) purchased from Selleck.

    Immunoblot analysis of pY-STAT3, EZH2, AKT, and trimethylated H3K27 in lysates from xenograft tumors treated with an AKT inhibitor perifosine.

    Cancer Cell 2013 23, 839-52. Perifosine (KRX-0401) purchased from Selleck.

  • Co-IP analysis of methylated STAT3 in GBM xenograft tumors treated with perifosine.AKT inhibition in vivo decreased STAT3 methylation and pY-STAT3, but increased global levels of H3K27 trimethylation.

    Cancer Cell 2013 23, 839-52. Perifosine (KRX-0401) purchased from Selleck.

    IF staining of pS21 EZH2 and pY-STAT3 on the frozen sections of GBM xenografts treated with vehicle or perifosine. Nuclei were stained with DAPI. Bar represents 10 microns.

    Cancer Cell 2013 23, 839-52. Perifosine (KRX-0401) purchased from Selleck.

  • NRP-152 cells were transfected with Id1-luciferase reporter element as described in the figure and then incubated with±perifosine (10 nmol/L)  for 2 hours, followed by±LR3-IGF-I (10 nmol/L) for 24 hours. Cells were then treated with ±BMP4 and assayed for luciferase 2 hours later.

     

     

    Cancer Res 2010 70, 9106-9117. Perifosine (KRX-0401) purchased from Selleck.

     

    LAT2 is degraded by proteasomes after treatment with alkylphospholipids. A, 3-h treatment of NB4 cells before exposure to the proteasome inhibitor MG132 (10 μM) prevented the reduction of LAT2 induced by 25 μM ODPC. B, C, a similar effect was observed after exposure (30 min) of NB4 cells to the proteasome inhibitor MLN9708 (5 μM) followed by treatment with 25 μM ODPC (B) or 25 μM perifosine (C).

    Mol Cell Proteomics 2012 11(12), 1898-1912 . Perifosine (KRX-0401) purchased from Selleck.

  • (a) Validation of the global proteome and acetylome results. AS and BE2 cells were treated with 10 μM of perifosine for 16 h. Total proteins were extracted and 30 μg of protein was analyzed for integrin β5 and acetyl-Histone H2B (Lys12) by western blotting. GAPDH was used as loading control.

    Sci Rep, 2017, 7:41950. Perifosine (KRX-0401) purchased from Selleck.

    Alkylphospholipid-induced morphological changes in HepG2 cells. Cell morphology was examined with an inverted microscope(20× original magnification). The morphology of HepG2 cells incubated with MEM/10% FBS is shown in the absence of any addition (control, A), or in the presence of 25 μM of HePC (B), edelfosine (C), ErPC (D) or perifosine (E) for 24 h. ErPC, erucylphosphocholine; FBS, fetal bovine serum; HePC, hexadecylphosphocholine; MEM, minimal essential medium.

     

     

    Brit J Pharmacol 2010 160, 355–366. Perifosine (KRX-0401) purchased from Selleck.

  • Knockdown of BRCA1 sensitizes cells to PI3K/AKT pathway inhibitors. MCF7 cells transfected with either BRCA1-siRNA or control-siRNA were treated with increasing amounts of inhibitors targeting the PI3K/AKT pathway for 48 h in triplicate. Viable cells were measured by MTT assay.

    Mol Carcinog 2012 ahead of print. Perifosine (KRX-0401) purchased from Selleck.

    Established cell lines (A549 and H460 lines) were un-stimulated (“C”, same for all figures), or treated with indicated concentration of perifosine (0.3-10 μM) or plus ABT-737 (100 nM), cells were then cultured for indicated time, and cell growth was tested by MTT assay (a, b, d, e) or by colony formation assay (c and f). “Prf” stands for perifosine (Same for all figures). The results presented were representative of three independent experiments. The values were expressed as the means ± SD. *p < 0.05 vs “C” group. #p < 0.05 compared with the perifosine only group without ABT-737 co-treatment.

    Biochem Biophys Res Commun, 2016, 473(4):1170-6. Perifosine (KRX-0401) purchased from Selleck.

  • Western blotting analysis demonstrating Ser473p-Akt and total Akt levels in HepG2 cells and Bel-7402 cells treated with increasing concentrations of perifosine for 24 h. Betaactin served as loading control. Bands were analyzed by Glyco Band-Scan software. Each bar corresponds to the mean ±SD for at least three independent experiments. * P<0.05,** P<0.01 vs. control, Student,s t test

     

     

    Cytotechnology 2010 62, 449-460. Perifosine (KRX-0401) purchased from Selleck.

    Induction of apoptosis in hepatoma cells by treatment for 48 h with 10 μM perifosine. The treated cells were stained with DAPI and the apoptotic morphological changes in the nuclear chromatin were observed under a fluorescent microscope.

    Cytotechnology 2010 62, 449-460. Perifosine (KRX-0401) purchased from Selleck.

  • Western blotting assay showing cleavage of caspase-3, caspase-9 and PARP in response to perifosine treatment in hepatoma cells. Each bar corresponds to the mean ±SD for at least three independent experiments. * P<0.05, ** P<0.01 vs. control, Student,s t test

    Cytotechnology 2010 62, 449-460. Perifosine (KRX-0401) purchased from Selleck.

    This chart showed the change of the stable transfection cells in centrosome separation after the cells were treated with perifosine(1 μM)  6 hours, 12 hours and 24 hours. "C" means the control group, and "P" means the group treated with perifosine

    2010 Zhao Jing PHD Medical College of Peking University. Perifosine (KRX-0401) purchased from Selleck.

  • TEIF (telomerase transcriptional elements-interacting factor)gene is a novel human gene and cloned from the expression library of  HeLa cell through the hTERT promoter-based yeast one-hybrid assay. And now we are trying to find the interaction between TEIF and the EGF pathway.

     

     

    2010 Zhao Jing PHD Medical College of Peking University . Perifosine (KRX-0401) purchased from Selleck.

     After starved in serum-free medium for 24h,T47D cells incubated with the indicated concentrations of Perifosine for 3h,followed by 15-minute  stimolation of 100ng/ml EGF.

     

     

     

    2010 Dr. Zhang of Tianjin Medical University. Perifosine (KRX-0401) purchased from Selleck.

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.
Targets
Akt [1]
(MM.1S cells)
4.7 μM
In vitro

Perifosine develops anti-proliferative properties with IC50 of 0.6-8.9 μM in immortalized keratinocytes (HaCaT), and head and neck squamous carcinoma cells. [1] Perifosine strongly reduces phosphorylation levels of Akt and extracellular signal-regulated kinase (Erk) 1/2, induces cell cycle arrest in G1 and G2, and causes dose-dependent growth inhibition of mouse glial progenitors. [2] Perifosine (10 μM) completely inhibits the phosphorylation of Akt in MM.1S cells. [3] A recent study demonstrates Perifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of Akt phosphorylation. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
T24 BC  NXTsdG1STnWwY4Tpc44hSXO|YYm= M3rEZVAvPS9zL{KuOUDPxE1? NVrPWWJEOyCq NHi2XVhz\WS3Y3XzJJRp\SCkYYPhcEBESiC2eYLvd4lv\SCyaH;zdIhwenmuYYTpc44hdGW4ZXzzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M1S2dFI3ODl5OEez
T24 BC  MnSwR4VtdCCYaXHibYxqfHliQYPzZZk> M3jvZVAvPS9zL{KuOUDPxE1? Mk[5NlQhcA>? MWTlcohidmOnczDzc5Ji\mWwaXKtbY5lfWOnZDDj[YxtKH[rYXLpcIl1gSCmZXPy[YF{\Q>? M4HlR|I3ODl5OEez
T24 BC  MormRZBweHSxc3nzJGF{e3OjeR?= M1\TelIvPSEQvF2= MXuyOEBp MVLz[Y5{cXSrenXzJGJEKGOnbHzzJJRwKHOxcnHm[Y5q[i2rbnT1Z4VlKGGyb4D0c5Rq[8Li MmPmNlYxQTd6N{O=
HepG2 MkfESpVv[3Srb36gRZN{[Xl? NVrGW4dMOjEEoN88US=> MnL0NlTDqGh? NVTsfnVzeHKxZIXj[ZMh[W5iaX70[Y5{\SCleYTvdIxie22rYzD2ZYN2d2yrenH0bY9vKGOxcoLld5BwdmSrbnegeI8h[SCwb4ThZoxmKGSrbHH0ZZRqd25ib3[geIhmKEWUIHPpd5Rmem6| MVGyOVk{PDJ|Mh?=
U-87 MG  Ml:xSpVv[3Srb36gRZN{[Xl? NUXOc|NVOjEEoN88US=> NXvMOnVtOjUEoHi= NX\KT2ozcW6lcnXhd4V{KGSxdXLs[U1u\W2kcnHu[UBjd3WwZDDzeJJ2[3S3cnXz NXPHVGFSOjV7M{SyN|I>
HepG2 MmP2SpVv[3Srb36gRZN{[Xl? MV2yNOKh|ryP NH7BSnk3NzJ2IHi= MYHpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCOQ{OtTWkh[2:2cnXheIVlKHerdHigR3E> NHjle44zPTl|NEKzNi=>
U-87 MG  NHTKT25HfW6ldHnvckBCe3OjeR?= Mn;PNlDDqM7:TR?= NGj4R2E3NzJ2IHi= NUm0ZoJOcW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[gUGM{NUmLIHPveJJm[XSnZDD3bZRpKEOT NUj5dIRwOjV7M{SyN|I>
HepG2 Mo\LSpVv[3Srb36gRZN{[Xl? MmnhNlDDqM7:TR?= NEXPbVY3NzJ2IHi= NXrBR4dS\GWlcnXhd4V{KEyFMz3JTUBl\We{YXTheIlwdsLiZoLvcUA3KGh? NIrBT3AzPTl|NEKzNi=>
U-87 MG  NWnwSVBUTnWwY4Tpc44hSXO|YYm= NIH6T3YzOMLizszN MYC2M|I1KGh? NGjGW3BqdmO{ZXHz[ZMhfGinIHH1eI9xcGGpaXOg[ox2gCBiYYSgOkBpKHeqaXzlJIlvcGmkaYTzJJRpcXNiZnz1fEBifCB{NHi= M2HRRVI2QTN2MkOy
HepG2 MlHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XDT|IxNzRyIN88US=> M1TxUFI1NzR6IHi= M{\wcolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NYnpN4dVOjV7M{SyN|I>
U-87 MG  NWrMXWZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3uzWFIxNzRyIN88US=> NXnMfHdbOjRxNEigbC=> MojSbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NUTCTlFGOjV7M{SyN|I>
A549 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M360bFAvOy1zMDFOwG0> NHW1eYIzPC95MjDo NVuwbmFxcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NWjwR5lvOjV4OUe4PVk>
H460 NX;FcY9QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfOO4MxNjNvMUCg{txO NWLzWG13OjRxN{KgbC=> NWDmdphTcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NV3DdplLOjV4OUe4PVk>
A549 Mo\jRZBweHSxc3nzJGF{e3OjeR?= NUTVXYczOS9|IN88US=> NULZZYN{PDhiaB?= NXTjSndkcW6mdXPld{BieG:ydH;zbZM> NWDD[o0zOjV4OUe4PVk>
H460 NFO3V3NCeG:ydH;zbZMhSXO|c3H5 M4\1bVEwOyEQvF2= Ml3BOFghcA>? NVTNRZN7cW6mdXPld{BieG:ydH;zbZM> NXnMS|FLOjV4OUe4PVk>
A549 Mn\rSpVv[3Srb36gRZN{[Xl? NGS2elQ{KM7:TR?= NYmweIpoQCCq NXrFfVho[myxY3vzJGFMXCCjY4TpeoF1cW:w NG\SV5UzPTZ7N{i5PS=>
H460 Mnn3SpVv[3Srb36gRZN{[Xl? MmjXN{DPxE1? M{DvUFghcA>? NWCwfINU[myxY3vzJGFMXCCjY4TpeoF1cW:w NEnnSIQzPTZ7N{i5PS=>
A549 M2LVUmZ2dmO2aX;uJGF{e2G7 NULPNIFpOyEQvF2= NE\ORnc5KGh? M{\1fYJtd2OtczDtWG9TSzFuIHHu[EBGWktvTVHQT{Bi[3SrdnH0bY9vKGOxbXLpcoVlKHerdHigUWVMNTF4Mh?= M{mw[VI2Pjl5OEm5
H460 NWrGNmQ{TnWwY4Tpc44hSXO|YYm= M3noNFMh|ryP NV3BPJV{QCCq MXjicI9kc3NibWTPVmMyNCCjbnSgSXJMNU2DUFugZYN1cX[jdHnvckBkd22kaX7l[EB4cXSqIF3FT{0yPjJ? MlvYNlU3QTd6OUm=
RMG1 M2LEemNmdGxiVnnhZoltcXS7IFHzd4F6 NUDafm1XOS1|MDFOwG0> NV;WPZFMPzJiaB?= MUnk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NHrPT2gzPTVzOUG0PC=>
RMG2 MVnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NV;kZmNHOS1|MDFOwG0> MmjyO|IhcA>? M3jZZoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MkjiNlU2OTlzNEi=
KOC7C M2jzcmNmdGxiVnnhZoltcXS7IFHzd4F6 NW\XW3VyOS1|MDFOwG0> NEjhOGE4OiCq MULk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NHi5bnYzPTVzOUG0PC=>
HAC2 NHGx[FdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MYexMVMxKM7:TR?= NIXjdIU4OiCq MUjk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NWm0cZBuOjV3MUmxOFg>
RMG2 M{HkSGNmdGxiVnnhZoltcXS7IFHzd4F6 NYLKXll{OS1|MDFOwG0> NETCOGg1QCCq NUDIOGU5\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy M1T3eVI2PTF7MUS4
OVISE MoG5R4VtdCCYaXHibYxqfHliQYPzZZk> MUmxMVMxKM7:TR?= MnTsOFghcA>? NYr0WlF[\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy M{X3WVI2PTF7MUS4
SKOV3 MUTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NVTKV|FGOS1|MDFOwG0> Mn:0OFghcA>? M3PvXoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NVixR3ZYOjV3MUmxOFg>
A2780 Mk[2R4VtdCCYaXHibYxqfHliQYPzZZk> MVSxMVMxKM7:TR?= NH;UdHY1QCCq Mm\q[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MXSyOVUyQTF2OB?=
RMG1 NFzzblZCeG:ydH;zbZMhSXO|c3H5 Mnv6N|Ah|ryP NFvobJYzPCCq NXrjS4NucW6mdXPld{BieG:ydH;zbZM> MX[yOVUyQTF2OB?=
RMG2 M{n5Z2Fxd3C2b4Ppd{BCe3O|YYm= NX7F[XhZOzBizszN NXfhPZBjOjRiaB?= NHHrd5lqdmS3Y3XzJIFxd3C2b4Ppdy=> NH\YfpIzPTVzOUG0PC=>
HCC1806 NFPQO|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrkdFlFOC1zMDFOwG0> M37IT|Q5KGh? MUfFR|UxRTJwOEVihKnDueLCiUCuNFch|ryP Mmq5NlUzQTN3N{[=
MDA-MB-231  MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXqxe21YOC1zMDFOwG0> NGDLPGg1QCCq Ml;ySWM2OD1zLkGz5qCKyrIkgJmwMlA4KM7:TR?= MlXWNlUzQTN3N{[=
GL-1 NIjkeFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml31NE4y6oDVMUCw5qCK|ryP MlnqOFghcA>? MmDNTWM2OD17LkmxJO69VQ>? M1LQblI1QDhzNUC4
CLBL-1 M36yNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn:4NE4y6oDVMUCw5qCK|ryP M3jtdVQ5KGh? M3vxSmlEPTB;M{OuNEDPxE1? NX\jWnh4OjR6OEG1NFg>
UL-1 M3zJS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHofZRsOC5z4pETNVAx6oDLzszN MoHyOFghcA>? NYr6WHNWUUN3ME23MlAyKM7:TR?= MV[yOFg5OTVyOB?=
Ema NXHRe2pST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2T3TlAvOeLCk{GwNQKBkc7:TR?= M4HtTFQ5KGh? M2nJOGlEPTB;NUiuO{DPxE1? MYeyOFg5OTVyOB?=
PANC-1 NYjZcoZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVewMVI2KM7:TR?= NYPMXW1LPzJiaB?= Mn\2bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> Mn\WNlQ2OTl5NUG=
MIA M4X5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfINE0zPSEQvF2= NWjWcpBFPzJiaB?= M4X3d4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MWmyOFUyQTd3MR?=
AsPC-1 M{m4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jSNVAuOjVizszN Mn7OO|IhcA>? M4rOcIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MlrYNlQ2OTl5NUG=
PANC-1 NIOwTnNHfW6ldHnvckBCe3OjeR?= M1\1e|AvPSEQvF2= Mki3NlQhcA>? NV3jXmEzcW6qaXLpeJMhSWu2LDDTOmsyNCCjbnSgSZJsOS9{IIDoc5NxcG:{eXzheIlwdsLi NVy0TWxrOjR3MUm3OVE>
MIA MX;GeY5kfGmxbjDBd5NigQ>? M3W5NFAvPSEQvF2= NVmxVHBIOjRiaB?= MonUbY5pcWKrdIOgRYt1NCCVNluxMEBidmRiRYLrNU8zKHCqb4PwbI9zgWyjdHnvcuKh Mn;5NlQ2OTl5NUG=
AsPC-1 NIXxWplHfW6ldHnvckBCe3OjeR?= NEfycoExNjVizszN MlS2NlQhcA>? M4LjdIlvcGmkaYTzJGFsfCxiU{\LNUwh[W6mIFXyb|EwOiCyaH;zdIhwenmuYYTpc47DqA>? M2jURVI1PTF7N{Wx
U87MG Mn3oR4VtdCCYaXHibYxqfHliQYPzZZk> M4O4[|AuOjVizszN NUTBfVE2OjRvOU[gbC=> NUXY[m5w\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGKxdHig[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVz MVOyOFA3PTV{Mh?=
SGC7901  NH7HTmhHfW6ldHnvckBCe3OjeR?= MYGwMlc2NzFywrFOwG0> MV:0PEBp MWHk[YNz\WG|ZYOgdE1Cc3RiKGPldkA1PzNrLDDwMWdUUzQQsjCoV4VzKDlrLDDhcoQhSy2PWVOgcIV3\Wy|wrC= MV6yN|kyOjJ2Nh?=
MGC803  MorHSpVv[3Srb36gRZN{[Xl? NEn4Z4oxNjd3L{GwxsDPxE1? Mnm1OFjDqGh? NVjoVXBx\GWlcnXhd4V{KHBvQXv0JEhU\XJiNEezLUwheC2JU1uz{tIhMFOncjC5LUwh[W6mIFOtUXlEKGyndnXsd:Kh NVXCV|NbOjN7MUKyOFY>
TykNu MnP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofhTWM2OD1|LkWg{txO NUfxOnFiOjN6N{ewNVI>
TykNuR MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TpfmlEPTB;NT61JO69VQ>? MWCyN|g4PzBzMh?=
M41 MoW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULhTnd2UUN3ME2yOE44KM7:TR?= NVjmbYc6OjN6N{ewNVI>
M41R M3:4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjxTWM2OD1zOT64JO69VQ>? NYLpPZI1OjN6N{ewNVI>
OVCAR8 MlLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXWTWM2OD1|MT6xJO69VQ>? NGPZV3gzOzh5N{CxNi=>
HeyA8 M4[w[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHWTWM2OD1{ND6zJO69VQ>? M1fvSVI{QDd5MEGy
A2780CP M4i5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1z2UWlEPTB;Nz62JO69VQ>? M1HFRVI{QDd5MEGy
OVCAR5 M3fwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPuTWM2OD14Lkeg{txO NVXWVIxQOjN6N{ewNVI>
A2780S NEPOVo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLz[WtGUUN3ME2xOE42KM7:TR?= MWKyN|g4PzBzMh?=
MCAS NV\tfpRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\KTWM2OD1zMj61JO69VQ>? NWHlcJFNOjN6N{ewNVI>
NCI-H727 MkDJR4VtdCCYaXHibYxqfHliQYPzZZk> NY\GPW5JOC1zMECg{txO NHHXT4czPC95MjDo M3rLc4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> NXPNW5BMOjJ2OUm0N|c>
GOT1 M3vHVGNmdGxiVnnhZoltcXS7IFHzd4F6 MXiwMVExOCEQvF2= MoriNlQwPzJiaB?= MV7k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= MXmyNlQ6QTR|Nx?=
BON1 NGTvR2RE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NX[wN2VkOC1zMECg{txO MnHVNlQwPzJiaB?= MX3k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= NYLpZXhDOjJ2OUm0N|c>
BON1 NXTIcW5nSXCxcITvd4l{KEG|c4PhfS=> MUmwMVExKM7:TR?= M3jVV|I1KGh? NGjNdo9qdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5 NEH1W2kzOjR7OUSzOy=>
BON1 NGrvO3hHfW6ldHnvckBCe3OjeR?= M4rjNFcvPS9zMDFOwG0> NGqx[VY5KGh? Mln6[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJJRp\SCjboTpMYFxd3C2b4TpZ{Bxem:2ZXnud{BDS0x{IHHu[EBD[2xvWFy= NI\UPWUzOjR7OUSzOy=>
Kasumi-1 MXTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NFrBPYsxNTJyIN88US=> MmGwNlQwPDhiaB?= M{HhN4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> M4PncVIzPDB5MkK4
HL-60 NHX2cYlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MWSwMVIxKM7:TR?= NEnpZnAzPC92ODDo NEDZ[ZRl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> Mlr0NlI1ODd{Mki=
Kasumi-1 MYjBdI9xfG:|aYOgRZN{e2G7 MXexNEDPxE1? NXLMXZBpOjRiaB?= MXPpcoR2[2W|IHHwc5B1d3Orcx?= Mo\ZNlI1ODd{Mki=
HL-60 M{XYbWFxd3C2b4Ppd{BCe3O|YYm= Mo\xNVAh|ryP MVmyOEBp NUfrUXBOcW6mdXPld{BieG:ydH;zbZM> NXz1UJJmOjJ2MEeyNlg>
Kasumi-1 M3Tn[mZ2dmO2aX;uJGF{e2G7 M{\tPVIvPS93L{GwJO69VQ>? NV6wNGV2OjRiaB?= MXrk[YNz\WG|ZYOgRYt1KGGwZDDwMWFsfCCuZY\lcJPDqGSxc3Wt[IVx\W6mZX70cJk> M3rWbVIzPDB5MkK4
HL-60 NHn2S3BHfW6ldHnvckBCe3OjeR?= MlnzNk42NzVxMUCg{txO MW[yOEBp NUjhSXpL\GWlcnXhd4V{KEGtdDDhcoQheC2Da4SgcIV3\Wy|wrDkc5NmNWSncHXu[IVvfGy7 MYSyNlQxPzJ{OB?=
Kasumi-1 NF\oOmZHfW6ldHnvckBCe3OjeR?= MX2yMlUwPS9zMDFOwG0> M2i0NVI1KGh? NFHQT4ZqdmS3Y3XzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiSl7LNU8zKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MW[yNlQxPzJ{OB?=
HL-60 M{OzVWZ2dmO2aX;uJGF{e2G7 MVqyMlUwPS9zMDFOwG0> M{LXXlI1KGh? MVHpcoR2[2W|IITo[UBxcG:|cHjvdplt[XSrb36gc4YhUk6NMT:yJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy NVnEfZNWOjJ2MEeyNlg>
K562 M1v3[GZ2dmO2aX;uJGF{e2G7 M3;MVlIxKM7:TR?= MXO0PEBp NVrwclU5cW6mdXPld{BifXSxcHjh[5nDqA>? M{DWPVIzPDB5MkK4
OCUT1 NIX1SZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXGwfGR{OC5zLUOg{txO M361NVUh\A>? M3vZbIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz M2fHO|IzODlyMkex
K1 M3TVVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzSNE4yNTNizszN MV[1JIQ> NXf6THRNcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M2PDNVIzODlyMkex
OCUT1 M3jld2Z2dmO2aX;uJGF{e2G7 NYrDc4FWOyEQvH2= MkPZNlQhcA>? NXfPdWFp[2G3c3XzJIEh\HKjbXH0bYMhcW6lcnXhd4UhcW5iR{KvUUBxcGG|ZR?= NV\WSlFEOjJyOUCyO|E>
CaOV3 MkfrR4VtdCCYaXHibYxqfHliQYPzZZk> MWexM|UwOTBizszN Ml;sOFghcA>? NWHmNoto\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXyJINwfHKnYYTl[EB4cXSqIIDhZ4xqfGG6ZXy= NWHFcpcyOjF5N{WwOVQ>
SKOV3 MYnDfZRwfG:6aXPpeJkhSXO|YYm= M3fJ[FUh|ryP MVm0PEBp NVf1fHh7\W6qYX7j[ZMheGGlbHn0ZZhmdCCrbnT1Z4VlKG:4YYLpZY4h[2GwY3XyJINmdGxiZHXheIjDqA>? NF3MemwzOTd5NUC1OC=>
A2780 MUHDfZRwfG:6aXPpeJkhSXO|YYm= NWXTOHkyPSEQvF2= MY[0PEBp NFXu[HNmdmijbnPld{Bx[WOuaYThfIVtKGmwZIXj[YQhd3[jcnnhckBk[W6lZYKgZ4VtdCCmZXH0bOKh MWiyNVc4PTB3NB?=
HT-29  MkjpR5l1d3SxeHnjbZR6KEG|c3H5 NW\vZWozPSEQvF2= MWq0PEBp M130ZoVvcGGwY3XzJJBi[2yrdHH4[YwhcW6mdXPl[EBwfmG{aXHuJINidmOncjDj[YxtKGSnYYToxsA> NVHWWo1KOjF5N{WwOVQ>
A498 NHeyVJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHEd|lbOC12MDFOwG0> MXm3NkBp MVvpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> M3O5SFIyPjR2MEWw
CAKI-1 MoGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7OelZ1OC12MDFOwG0> MWi3NkBp MVjJR|UxhjFyIN88US=> MVOyNVY1PDB3MB?=
769-P MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVqwMVQxKM7:TR?= NXjCW2t{PzJiaB?= MVHJR|UxhjVvMUCg{txO NWHuVXNDOjF4NESwOVA>
786-0 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXLc2oxNTRyIN88US=> M4HrNVczKGh? MUPJR|UxhjVizszN M3nmZ|IyPjR2MEWw
786-O NFjiUGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\DO|AuOjBizszN M3fWWFczKGh? M{W1XIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MWSyNVY1PDB3MB?=
CAKI-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTJOG5KOC1{MDFOwG0> MWq3NkBp MV\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NVfJT3dpOjF4NESwOVA>
769-P NELEcldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmr0NE0zOCEQvF2= NGnDR4Y4OiCq NGDyeVlqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MXKyNVY1PDB3MB?=
A498 NEjISHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYKwMVIxKM7:TR?= NIXUXJM4OiCq M2\id4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz M{DpRlIyPjR2MEWw
CWR22RV1 MVvD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M{\GTFExKM7:TR?= NH65Z2QzPCCq MXvpcoNz\WG|ZYOgd4Vve2m2aY\peJkhd2ZiaIXtZY4hS1eUMkLSWlEh[2WubIOgeI8hemGmaXH0bY9v NFrJVoczOTR7NkK3Ny=>
CWR22RV1 MWLBdI9xfG:|aYOgRZN{e2G7 NGCzfo8yOCEQvF2= MnjkNlQhcA>? NHHHeGhmdmijbnPld{Bz[WSrYYTpc44hcW6mdXPl[EBieG:ydH;zbZM> NHLXXmkzOTR7NkK3Ny=>
CWR22RV1 NVLOcY1wTnWwY4Tpc44hSXO|YYm= M4\Kc|Uh|ryP NVzGR2hIOjRiaB?= NVHNWHFWemWmdXPl[EBxcG:|cHjvdplt[XSrb36gc4YhSWu2IIPp[45q\mmlYX70cJk> NWXHc|A4OjF2OU[yO|M>
HepG2  NWXHNHltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUW1M|ExNzJyL{SwJO69VQ>? M1PXR|I1NzR6L{eyJIg> Mn\KbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M4TQSVIxQDR{NEK1
Bel-7402 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLmO4tUPS9zMD:yNE81OCEQvF2= M{X0b|I1NzR6L{eyJIg> NHnKPYNqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MYGyNFg1OjR{NR?=
HepG2  MVnGeY5kfGmxbjDBd5NigQ>? MV21M|ExNzJyIN88US=> M1XBRVI1KGh? MmnQdoV{fWy2czDpckB1cGViYXPjeY12dGG2aX;uJI9nKGOnbHygcpVu[mW{IHnuJJRp\SCJMj;NJJBp[XOn NH7hb|EzODh2MkSyOS=>
Bel-7402 NHn6U3dHfW6ldHnvckBCe3OjeR?= NYfVU2hNPS9zMD:yNEDPxE1? M1W4ZlI1KGh? MlvRdoV{fWy2czDpckB1cGViYXPjeY12dGG2aX;uJI9nKGOnbHygcpVu[mW{IHnuJJRp\SCJMj;NJJBp[XOn MljrNlA5PDJ2MkW=
HepG2  NIjHZVdCeG:ydH;zbZMhSXO|c3H5 MVi1M|ExNzJyIN88US=> M2XqSlI1NzR6IHi= M1WwWolv\HWlZYOgZZBweHSxc3nzJIF1KHSqZTDsc45oNXSrbXWg[Zhxd3O3cnW= MV:yNFg1OjR{NR?=
Bel-7402 MWXBdI9xfG:|aYOgRZN{e2G7 NUPFOIEzPS9zMD:yNEDPxE1? MofHNlQwPDhiaB?= M1PiV4lv\HWlZYOgZZBweHSxc3nzJIF1KHSqZTDsc45oNXSrbXWg[Zhxd3O3cnW= MkW1NlA5PDJ2MkW=
OAW-42 M37rRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUGwMVQxKM7:TR?= NHLsW3Q4OsLiaB?= NHXEOoxKSzVyfkGwJO69VSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= Mkn6NlA1ODV{OU[=
PA-1  MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nWXFAuPDBizszN NFjlNJk4OsLiaB?= MnHiTWM2OH5{NTFOwG0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ Mlu5NlA1ODV{OU[=
SKOV3  NVn6Z3N3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUWwMVQxKM7:TR?= NE\JOJY4OsLiaB?= MYnJR|UxhjNyIN88UUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MoDSNlA1ODV{OU[=
A2780 M{m5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmThNE0zOCEQvF2= MmrFOFgwPzJiaB?= MXzJR|UxyqB;wrCzxsDPxG1? NV7RUYVHOjB2MEWyPVY>
A2780cis  M4Hte2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVWwMVIxKM7:TR?= NX62UmpyPDhxN{KgbC=> MX3JR|UxyqB;wrC2xsDPxG1? NF7Jd3gzODRyNUK5Oi=>
SKW6.4 NF;BT2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDrNk0yOMLizszN NFe4OYw1QMLiaB?= NXrtXXVPcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NFH1NHkzODF|MEm2NC=>
MAVER M{nyNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofaNk0yOMLizszN NUTzN5hTPDkEoHi= NEC4OI5qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MnjpNlAyOzB7NkC=
BJAB NYTFNHpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XmXlIuOTEEoN88US=> M{\MVVQ5yqCq MlfMbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NU[3RYVJOjBzM{C5OlA>
OCI NEH3ZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrqO4UzNTFywrFOwG0> MkX5OFjDqGh? NIf1bHRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MXSyNFE{ODl4MB?=
MOLM MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moq4Nk0yOMLizszN MX[0POKhcA>? MXfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MUGyNFE{ODl4MB?=
HL-60 NWTUc4tzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2S1[|IuOTEEoN88US=> M3n2VVQ5yqCq NV3tXIY6cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NWD3bHljOjBzM{C5OlA>
SKW6.4 NFO4T3BCeG:ydH;zbZMhSXO|c3H5 MXyxNOKh|ryP MUWyOE81QCCq MlfLbY5lfWOnczDhdI9xfG:|aYOgeIlu\S2mZYDlcoRmdnSueR?= MYSyNFE{ODl4MB?=
MAVER MorMRZBweHSxc3nzJGF{e3OjeR?= MUexNOKh|ryP NYW5U|V2OjRxNEigbC=> M3fNeIlv\HWlZYOgZZBweHSxc3nzJJRqdWVvZHXw[Y5l\W62bIm= NVvlbnZLOjBzM{C5OlA>
BJAB M16ySmFxd3C2b4Ppd{BCe3O|YYm= NVGzWIh7OTEEoN88US=> NWezNmtSOjRxNEigbC=> MkD4bY5lfWOnczDhdI9xfG:|aYOgeIlu\S2mZYDlcoRmdnSueR?= MkS2NlAyOzB7NkC=
OCI NHzFfZZCeG:ydH;zbZMhSXO|c3H5 MXexNOKh|ryP MUOyOE81QCCq MlHabY5lfWOnczDhdI9xfG:|aYOgeIlu\S2mZYDlcoRmdnSueR?= M{HyRlIxOTNyOU[w
MOLM M4LLUmFxd3C2b4Ppd{BCe3O|YYm= NX\HSlJnOTEEoN88US=> MkfvNlQwPDhiaB?= NVHWNXMzcW6mdXPld{BieG:ydH;zbZMhfGmvZT3k[ZBmdmSnboTsfS=> NFHYZnYzODF|MEm2NC=>
HL-60 MVzBdI9xfG:|aYOgRZN{e2G7 NFzTV5oyOMLizszN M3;oVFI1NzR6IHi= NGHpVnBqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nLXTldIVv\GWwdHz5 MYqyNFE{ODl4MB?=

... Click to View More Cell Line Experimental Data

In vivo Perifosine combining with temozolomide reduces tumor proliferation (a PDGF-driven gliomagenesis) in vivo. The results indicate that Perifosine is an effective drug in gliomas in which Akt and Ras-Erk 1/2 pathways are frequently activated, and may be new candidate for glima treatment in the clinic. [2] Both oral daily and weekly administration of Perifosine significantly reduce human MM tumor growth and increase survival, compared with control animals treated with PBS vehicle only. [3] Perifosine induces thrombocytosis and leukocytosis and increases myelopoiesis in murine marrow and spleen, whereas it causes apoptosis in myeloma xenografts. [5]

Protocol

Kinase Assay:[3]
+ Expand

Akt kinase assay:

MM.1S cells are cultured in the presence or absence of perifosine (5 μM, 6 hours) and then stimulated with IL-6 (20 ng/mL, 10 minutes). In vitro akt kinase assay is then carried out using the Akt Kinase Assay Kit.
Cell Research:[2]
+ Expand
  • Cell lines: Human glioma cell lines
  • Concentrations: 0, 15, 30 and 45 μM
  • Incubation Time: 48 hours
  • Method: Cells are incubated in the medium with 10% FCS for 48 hours with indicated concentration of Periosine. Cell viability is determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. (Cell Proliferation Kit I; Roche). The absorbance at 590 nm is recorded using the 96-well plate reader.
    (Only for Reference)
Animal Research:[3]
+ Expand
  • Animal Models: MM.1S MM cells are inoculated subcutaneously in the right flank of Beige-nude-xid (BNX) mice (5 to 6 weeks old).
  • Formulation: 0.9% NaCl solution
  • Dosages: 250 mg/kg/wk or 36 mg/kg/d
  • Administration: Oral gavage
    (Only for Reference)

Solubility (25°C)

In vitro Ethanol 15 mg/mL (32.49 mM)
Water 8 mg/mL (17.32 mM)
DMSO Insoluble
In vivo Add solvents to the product individually and in order:
water
For best results, use promptly after mixing.
8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 461.66
Formula

C25H52NO4P

CAS No. 157716-52-4
Storage powder
Synonyms NSC639966

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02238496 Active, not recruiting Brain Tumor, Recurrent|Glioblastoma|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Mixed Glioma Andrew Lassman|Pfizer|AEterna Zentaris|Columbia University July 2014 Phase 2
NCT01224730 Unknown status Cancer AEterna Zentaris January 2012 Phase 1
NCT01097018 Completed Colorectal Cancer AEterna Zentaris April 2010 Phase 3
NCT01049841 Active, not recruiting Pediatric Solid Tumors Memorial Sloan Kettering Cancer Center|University of Wisconsin, Madison|Duke University|NATL COMP CA NETWORK|Pfizer|AEterna Zentaris January 2010 Phase 1
NCT01051557 Active, not recruiting Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Diffuse Astrocytoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Adult Oligodendroglioma|Recurrent Adult Brain Neoplasm National Cancer Institute (NCI) January 2010 Phase 1|Phase 2
NCT01002248 Terminated Multiple Myeloma AEterna Zentaris|Dana-Farber Cancer Institute December 2009 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

Related Akt Products

Tags: buy Perifosine (KRX-0401) | Perifosine (KRX-0401) supplier | purchase Perifosine (KRX-0401) | Perifosine (KRX-0401) cost | Perifosine (KRX-0401) manufacturer | order Perifosine (KRX-0401) | Perifosine (KRX-0401) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID